Trial Profile

Study of MK-6240 SUVR to characterize of tau PET according to amyloid chronicity

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Florquinitau F18 (Primary)
Indications Alzheimer's disease; Tauopathies
Focus Diagnostic use

Most Recent Events

14 Aug 2026 According to an Enigma Biomedical media release, the U.S. Food and Drug Administration (FDA) approve of florquinitau F 18 injection (TAUKLARIFY) for positron emission tomography (PET) of the brain in adults with cognitive impairment who are being evaluated for Alzheimers disease to identify patients with tau neurofibrillary tangle (NFT) pathology.
09 Sep 2022 New trial record
04 Aug 2022 Results presented at the Alzheimer's Association International Conference 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com